Eli Lilly's stock price hit a record high and analysts raised their target prices.
On October 22, Eli Lilly's stock price bucked the trend and rose nearly 4%, hitting a new historical high, with a cumulative increase of more than 22% since the beginning of the year. Analysts raised their price targets due to strong demand for Mounjaro and Zepbound, as well as capital investment to expand global production facilities.